Search the Newsreel

Cycurion beats revenue & EPS estimates; lands $54.6M 10-year contract, gross margin jumps to 29.1%

Cycurion (CYCU) reported strong Q2 results, exceeding revenue and EPS estimates. The company secured a significant $54.6 million, 10-year contract and saw its gross margin increase substantially to 29.1%. Acquisitions also contributed to a boosted revenue run rate.

Stifel reiterates Buy rating on Oculis stock, $40 target

Stifel has reiterated a Buy rating and a $40 price target for Oculis Holding AG (NASDAQ:OCS), based on discussions about its lead asset, privosegtor. Despite a recent stock drop and an "overvalued" assessment by InvestingPro, analysts maintain a strong buy consensus. Oculis is shifting …

Stifel cuts Celcuity stock price target on refined market model

Stifel lowered its price target for Celcuity Inc. (NASDAQ:CELC) to $150 from $175, while maintaining a Buy rating, citing refined market model inputs for Revtorpyk and higher future administrative expenses. Despite the stock's strong performance, InvestingPro analysis suggests it might be overvalued, and analysts …

Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% Upside

Analysts have adjusted Celcuity Inc.'s average 12-month price target from $163.55 to $160.64, with individual forecasts ranging from $140 to $178 per share. This new target suggests an 85% potential upside from the Aug. 13 closing price. The consensus rating for Celcuity Inc. remains …

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?

Shares of Oculis Holding AG (OCS) have recently gained 1.7%, and Wall Street analysts project a potential rally of 187.83%, with a mean estimate of $36.9. Despite the inherent skepticism surrounding analyst price targets, a strong agreement among analysts on OCS's earnings potential and …

Cycurion (NASDAQ: CYCU) boosts margins, lands $54.6M contract in Q2 update

Cycurion (NASDAQ: CYCU) reported Q2 2026 revenues of $3.8 million, beating Wall Street estimates, and saw a significant improvement in gross margin to 29.1% from 6.1% year-over-year. The company also announced a landmark $54.6 million, 10-year contract and made strategic acquisitions, contributing to an …

Moleculin Biotech GAAP EPS of -$1.40 misses by $0.53

* Moleculin Biotech press release [https://seekingalpha.com/pr/20619725-moleculin-biotech-reports-second-quarter-2026-financial-results-and-highlights-continued] (MBRX [https://seekingalpha.com/symbol/MBRX]): Q2 GAAP EPS of -$1.40 misses by $0.53. * As of June 30, 2026, the company had cash and cash equivalents of approximately $7.3 million. Management believes that its cash on hand and cash equivalents as …

CITIC Securities: The Hang Seng TECH Index is expected to undergo a significant revision, with changes to constituent stocks taking effect as early as the December index rebalancing date.

Marcus & Millichap arranges $5m sale of industrial warehouse at 93 Mystic Ave., Medford, MA

Marcus & Millichap has successfully arranged the $5 million sale of an industrial property located at 93 Mystic Ave. in Medford, MA. The 19,278 sq ft property, comprising two buildings and designed for food processing, was sold to a private family. The asset's core …

Ocugen, Inc. (NASDAQ:OCGN) Receives Average Rating of "Moderate Buy" from Analysts

Ocugen, Inc. (NASDAQ:OCGN) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $9.50. Insider buying by CFO Treerita Essali Johnson-Greene and increased institutional holdings indicate positive sentiment, though the stock has been under pressure after reporting a …

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Moleculin Biotech reported its second-quarter 2026 financial results, highlighting significant progress in its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory AML. Positive interim data showed complete remission rates three times higher than the control group, with enrollment on track for …

CuriosityStream: The 40% Stock Surge Was Warranted (Rating Upgrade) (NASDAQ:CURI)

Needham cuts Celcuity stock price target on updated revenue model

Needham has reduced its price target for Celcuity Inc (NASDAQ:CELC) shares to $140 from $157, while maintaining a Buy rating. This adjustment follows the approval and upcoming launch of Revtorpyk, with Needham updating its revenue models to an incidence-based approach and incorporating new pricing …

Driehaus Capital discloses 6.96% Cue Biopharma (CUE) holding in Schedule 13G

Driehaus Capital Management LLC has disclosed a 6.96% beneficial ownership stake in Cue Biopharma, Inc. (CUE), amounting to 292,144 shares. This holding is reported on a Schedule 13G filing, indicating a passive investment. The shares are held in fully discretionary accounts for investment advisory …

Scully Royalty Installs Executive Chairman as Interim CEO and CFO

PZ Cussons Publishes 2026 Annual Report and Sets Date for AGM

Allegro Culture Signals Return to Profit on Advertising Growth

Acumen's Q2 Loss Narrows; Topline Phase 2 Data For Alzheimer's Drug Sabirnetug In Late '26

(RTTNews) - Acumen Pharmaceuticals Inc. (ABOS), a clinical-stage biopharmaceutical company, on Wednesday announced second quarter financial results and noted a lower net loss owing to reduced research and development (R&D) expenses. The company is engaged in developing novel therapeutics targeting toxic soluble amyloid beta …

Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at Zacks Research

Zacks Research upgraded Ocular Therapeutix (NASDAQ:OCUL) from a "strong sell" to a "hold" rating. Despite this change, the consensus among analysts remains a "Moderate Buy" with an average price target of $25.75, reflecting broad positive sentiment. The company recently reported better-than-expected quarterly results, with …

Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G

Polar Capital Holdings Plc and Polar Capital LLP have disclosed a 5.28% ownership stake in Arcutis Biotherapeutics, Inc. (ARQT) through a Schedule 13G filing. The investment firm beneficially owns 6,606,945 shares, with sole voting and dispositive power, based on Arcutis's 125,083,374 outstanding shares as …

Scully Royalty Ltd. (NYSE: SRL) shifts chairman into interim CEO and CFO roles

Scully Royalty Ltd. has appointed its Chairman, Michael J. Smith, as interim Chief Executive Officer and Chief Financial Officer, replacing Samuel Morrow who will now serve as a non-executive director. Smith will oversee executive leadership while the company searches for permanent replacements. The company …

Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals

Abacus Global Authorized To Repurchase $100 Mln Of Shares

(RTTNews) - Abacus Global Management, Inc. (ABX), a financial service provider, said that its board has authorized a $100 million share repurchase program, commencing August 17. This authorization aligns with the company's capital allocation framework. Jay Jackson, CEO of Abacus, said: "This repurchase authorization …

Celestial Asia Clarifies Terms of Share Option Incentive Scheme

New Focus Auto Tech Sets Board Meeting to Review Interim Results and Dividend

Ocumension Sets August Board Meeting to Approve Interim Results and Consider Dividend

Celestial Asia Sets August Board Meeting to Approve Interim Results

Q2 Rundown: Curtiss-Wright (NYSE:CW) Vs Other Aerospace Stocks

Q2 Rundown: Curtiss-Wright (NYSE:CW) Vs Other Aerospace Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at Curtiss-Wright (NYSE:CW) and the best and worst performers …

Marcus & Millichap (MMI) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 10:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Hessam NadjiChief Financial Officer - Steve DeGennaro TAKEAWAYS Total Revenue -- $203 million, an 18% increase compared to $172 million in the …

Hercules Capital closes $300 million notes offering at 5.35% interest By Investing.com

Hercules Capital (NYSE:HTGC) has successfully closed an underwritten public offering of $300 million in 5.350% notes due February 10, 2029. The specialty finance company plans to use the net proceeds to fund investments, repay existing secured debt, and for general corporate purposes. This move …

Allegro Culture Sets Board Meeting to Approve Interim Results

Acusensus (ASX:ACE) Surges as Road Safety Technology Captures Strong Demand

China Cultural Tourism and Agriculture Group Sets Board Meeting on Interim Results and Dividend

Quantinno Capital Management LP Acquires 40,335 Shares of Marcus & Millichap, Inc. $MMI

Quantinno Capital Management LP significantly increased its stake in Marcus & Millichap (NYSE:MMI) by 348.4% in the first quarter, acquiring an additional 40,335 shares to bring its total holding to 51,913 shares. The real estate investment trust reported strong financial results, beating analysts' consensus …

Cummins Inc (CMI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cummins Inc (CMI), highlighting its current price momentum score of 3.62 and its trading range between support at 582.44 and resistance at 676.06. It details various technical indicators and moving averages, offering buy, sell, and neutral signals …

Orient Securities Sets Board Meeting to Approve 2026 Interim Results